Brainstorm Cell Therapeutics Inc
(STU:GHD)
€
2.979
0 (0%)
Market Cap: 9.73 Mil
Enterprise Value: 7.41 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 36/100 Brainstorm Cell Therapeutics Inc looks forward to top-line results for its ALS Phase 3 program Transcript
Jan 15, 2020 / NTS GMT
Release Date Price:
€57.6
(-0.52%)
Christine Corrado
Proactive Investors Limited - Moderator
Hello, and welcome to day two here at the biotech showcase 2020 in San Francisco. I am Christine Corrado with Proactive. Joining me right now is Ralph Kern. He is the COO and Chief Medical Officer at Brainstorm Cell Therapeutics. Ralf, great to see you.
Ralph Kearney
Brainstorm Cell Therapeutics - COO and Chief Medical Officer
Thanks, Christine. Pleasure to be here.
Christine Corrado
Proactive Investors Limited - Moderator
Ralf, we talked about a year ago in this same exact place. First off just remind investors about the company.
Ralph Kearney;Christine Corrado
Brainstorm Cell Therapeutics - COO and Chief Medical Officer;Proactive Investors Limited
Yes, we're a biotech company that's focused on developing cellular therapeutics for neurodegenerative diseases. And we have ALS program, which is in Phase 3, fully enrolled and we're going to have data in the fourth quarter of this year.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot